Quarterly Report II 17/18
September 2017 – February 2018, Diamyd Medical AB (publ), Fiscal year 2017/2018September 1, 2017 – February 28, 2018 · Net result amounted to MSEK -20.0 (-10.9), of which the second quarter constituted of MSEK -9.1 (-6.4). The change compared with the previous year relates to the DIAGNODE-2 trial which started this financial year and production of GAD-65 · Result per share, before and after dilution, amounted to SEK -0.4 (-0.4), of which the second quarter constituted of SEK -0.2 ( -0.2) · Cash flow from operating activities amounted to MSEK -22.9 (-10.5) of which the second